Mounjaro Safety Guide

Mounjaro side effects: what the data actually shows

Published by GLP-1 Picks · AI-assisted editorial research · Updated October 23, 2026

Important: Mounjaro is FDA-approved for type 2 diabetes

Mounjaro (tirzepatide) is approved by the FDA to treat type 2 diabetes. It is not FDA-approved for weight loss.

The same active molecule (tirzepatide) is also marketed under the brand name Zepbound, which IS FDA-approved for chronic weight management.

The common-side-effect table below reports 5 mg, 10 mg and 15 mg groups from two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 and SURPASS-5).

It does not give rates for every dose or population. For the weight-management product, see the Zepbound side effects deep dive.

The most common Mounjaro side effects at diabetes doses are gastrointestinal: nausea (12% at 5mg / 15% at 10mg / 18% at 15mg), diarrhea (12-17%), decreased appetite (5-11%), and vomiting (5-9%) in the cited adult placebo-controlled trials.

These percentages do not predict your symptoms or when they will occur. Mounjaro is a dual GIP/GLP-1 receptor agonist.

The trial percentages below come from the FDA-approved Mounjaro prescribing information.

Warning signs: when to seek medical help

• Severe or persistent abdominal pain, with or without vomiting: stop Mounjaro and contact your healthcare professional right away; pain may reach your back.
• Shakiness, sweating, confusion or drowsiness, or a fast heartbeat can be signs of low blood sugar. Follow the plan your clinician gave you, especially if you also use insulin or a sulfonylurea.
• Symptoms of a serious allergic reaction, such as breathing difficulty or throat swelling: stop Mounjaro and get medical help right away.
• Changes in vision: contact your clinician, including if you have a history of diabetic retinopathy.
• Persistent nausea, vomiting, or diarrhea: contact your clinician promptly about possible dehydration; do not wait for a fixed number of hours.
• Upper abdominal pain, fever, jaundice, or clay-colored stools: contact your clinician right away about possible gallbladder problems.

If you are experiencing a medical emergency, call 911.

Report any serious adverse event to FDA MedWatch.

Common side effects: rates from the Mounjaro label

Source: section 6.1, Table 1 of the FDA-approved Mounjaro prescribing information.

These 5 mg, 10 mg and 15 mg rates pool two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 and SURPASS-5).

Each percentage counts people who reported the symptom at least once; it does not describe its severity or duration.

Side effect	5mg	10mg	15mg
Nausea	12%	15%	18%
Diarrhea	12%	13%	17%
Decreased appetite	5%	10%	11%
Constipation	6%	6%	7%
Dyspepsia (indigestion)	8%	8%	5%
Vomiting	5%	5%	9%
Abdominal pain	6%	5%	5%

How do dose changes affect symptoms?

Reported nausea, vomiting and diarrhea can occur during dose increases. Trial percentages do not tell you which week a symptom will start or stop.

Follow your prescriber's instructions for your exact product and indication, and contact them about troublesome symptoms before changing your dose.

The Mounjaro prescribing information, section 2 explains the dosing instructions. It is a reference for your clinician, not a schedule to advance through automatically.

What should you ask your prescriber about side effects?

Describe the symptom, when it started, your current dose and your most recent dose change.
Explain whether eating, drinking or daily activities are affected. Persistent or severe symptoms need clinical assessment.
For routine symptoms, ask your clinician before changing Mounjaro, insulin or sulfonylureas. Follow the urgent instructions above if those warning signs occur.
Ask which symptoms require urgent help and how to contact the care team between appointments.

Use the Mounjaro prescribing information and Medication Guide alongside this checklist. For help recording symptoms and preparing questions, see our symptom-management guide.

FDA's January 2026 review found no increased risk of suicidal thoughts or behavior with GLP-1 medicines.

Mood changes still deserve care: tell your clinician about new or worsening depression or suicidal thoughts. Call or text 988 for crisis support; call 911 for immediate danger.

Serious side effects, recognize these red flags

This is not a complete list of warnings or possible side effects. Use the full prescribing information and Medication Guide with your clinician. The Mounjaro label calls for monitoring people with a history of diabetic retinopathy; ask your clinician what monitoring you need.

Pancreatitis

Reported in clinical trials; requires urgent assessment

Red-flag symptoms: Severe or persistent abdominal pain that may reach your back, with or without nausea or vomiting

Action: Stop Mounjaro and contact your healthcare professional right away if pancreatitis is suspected.

Diabetic retinopathy complications

Label warning: monitor people with a history of diabetic retinopathy

Red-flag symptoms: New or worsening blurred vision, especially in patients with pre-existing diabetic retinopathy. Rapid improvement in blood glucose can transiently worsen retinopathy in vulnerable patients.

Action: Tell your clinician about any history of diabetic retinopathy and any vision changes. Ask what eye monitoring is appropriate for you.

Gallbladder problems

Acute gallbladder disease: 0.6% vs 0% on placebo in adult placebo-controlled trials

Red-flag symptoms: Upper abdominal pain, fever, jaundice, or clay-colored stools

Action: Contact your clinician right away for these symptoms. They can assess whether gallbladder tests and follow-up are needed.

Acute kidney injury

Reported, including after fluid loss from vomiting or diarrhea

Red-flag symptoms: Persistent nausea, vomiting, or diarrhea that can lead to dehydration

Action: Contact your clinician promptly for ongoing vomiting or diarrhea, trouble keeping fluids down, or signs of dehydration. Do not wait for a fixed number of hours.

Severe hypoglycemia

Risk is increased with insulin or sulfonylureas

Red-flag symptoms: Shakiness, sweating, confusion or drowsiness, blurred vision, or a fast heartbeat

Action: Follow the low-blood-sugar plan agreed with your clinician. Contact them about symptoms and ask whether insulin or sulfonylurea doses need review.

Severe allergic reaction (anaphylaxis)

Reported; can be life-threatening

Red-flag symptoms: Difficulty breathing or swallowing, swelling of the face, lips, tongue or throat, severe rash or itching, or faintness

Action: Stop Mounjaro and get medical help right away for a suspected serious allergic reaction.

The boxed warning: thyroid C-cell tumors

Mounjaro carries a boxed warning for thyroid C-cell tumors. This is based on rodent studies; the human risk is unknown.

Mounjaro is contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• A known serious allergic reaction to tirzepatide or any Mounjaro ingredient

Tell your prescriber about your personal and family thyroid history and any serious medication allergies before starting Mounjaro.

Choosing a provider for Mounjaro

Ask about diabetes care and clinical support before enrolling.

Ask whether your clinician will:

Review your diabetes history, including any retinopathy
Review insulin, sulfonylureas and other medicines with you
Explain your individual glucose-monitoring and follow-up plan
Give you a plan for low blood sugar and urgent symptoms

Confirm whether a service manages type 2 diabetes, how it coordinates with your existing clinician, and who handles questions between visits.

Compare each program's current clinical-oversight evidence in our full rankings. Overall scores are not a medical-safety endorsement.

Ask your existing diabetes clinician about continuity of care before changing services.

Our Sprout Health review is a starting point for program research, not a recommendation for managing your symptoms.

Explore program costs and recorded support options in the program finder, or take the 60-second match quiz to explore program options.

Zepbound side effects deep dive : same molecule (tirzepatide) at the weight-loss indication
Ozempic side effects deep dive : semaglutide, another medicine approved for type 2 diabetes
Wegovy side effects deep dive
Foundayo side effects deep dive
Cross-drug GLP-1 side effects comparison
Mounjaro and GLP-1 lawsuit tracker
FDA warning letter tracker

Sources

This page is for informational purposes only and is not medical advice. Always discuss medication decisions with a licensed prescriber.

Mounjaro is FDA-approved for type 2 diabetes mellitus in adults.

Side-effect rates are population averages from clinical trials and may not reflect your individual experience. If you are experiencing a medical emergency, call 911.